7:00 PM

Conference Registration

8:00 PM

Welcome Reception and Dinner

8:00 AM

Breakfast

8:50 AM

Welcome and Opening Remarks

John Lambris

SESSION I

Complement in cancer: mechanistic insights and therapeutic concepts

Chairs: Ruben Pio and Lubka Roumenina

9:00 AM

1

C5a/C5aR1 signaling in the myeloid compartment of the tumor microenvironment: Implications for cancer immunotherapy

Ruben Pio

9:20 AM

2

Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression

Cecilia Garlanda

9:40 AM

3

In situ complementomics reveals intratumoral complement activation and intracellular functions of complement proteins, leading to poor prognosis in renal cancer

Lubka Roumenina

10:00 AM

4

The role of prostasomes and tissue kallikreins in coagulation disorder associated with the prostate cancer

Vivek Anand Manivel, Bo Nilsson, Kristina Ekdahl, Claudia Duhrkop, David Eikrem, Anna Adler, Karin Formell, and Oskar Eriksson

10:15 AM

Coffee Break and Poster Viewing

SESSION II

Therapeutic development: novel complement inhibitors

Chairs: Antonio Risitano, Daniel Ricklin

11:00 AM

5

Preclinical studies establishing C3 as a target of host-modulation therapy in periodontal disease

George Hajishengallis and John Lambris

11:20 AM

6

Clinical development of the compstatin-based C3 therapeutic AMY-101 as a novel host modulation therapy for periodontal inflammation

Hatice Hasturk, George Hajishengallis, The Forsyth Institute Center for Clinical and Translational Research staff, Dimitrios C. Mastellos, Despina Yancopoulou and John D. Lambris

11:40 AM

7

Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors

Christina Lamers, Martin Smiesko, Xiaoguang Xue, Henri van Son, Bea Wagner, Georgia Sfyroera, Piet Gros, John Lambris, and Daniel Ricklin

11:55 PM

8

From academic to (pre-)clinic: Expanding the repertoire of complement inhibitors for research and therapy

Daniel Ricklin, Kevin Widmer, Clément Bechtler, Ekaterina Umnyakova, Rachel Hevey, Carla Plüss, Aleksandra Blagojevic, Bea Wagner, Christina Lamers, Oliver Schwardt, Said Rabbani, and Richard Pouw

12:15 PM

9

Complement Factor I (CFI) as a protease medicine: Engineered new therapeutics for complement-mediated disorders

Natacha Le Moan, Lauren Kelly, Shyam Iyer, Emil Oldenburg, Agnieszka Jendroszek, Christine Schar, Jan Jensen, Jim McGuire, and Grant Blouse

12:30 PM

10

The Odyssey of anti-complement treatment in PNH is gone: bringing proximal inhibitors into the clinic

Antonio Risitano

12:50 PM

Lunch and Informal Discussions

7:30 PM

Dinner and Informal Discussions

September 10

SESSION III

Therapeutic development: novel complement inhibitors

Chairs: Mihály Józsi and Tom Mollnes

9:15 AM

11

A panel of monoclonal antibodies against complement proteins for interfering with multiple steps of complement activation

Mihály Józsi, Barbara Uzonyi, Alexandra Papp, Alexandra Matola, Mátka Nagy, Boglárka Kovács, Márton Rabb, Zsóka Szabó, Marcell Cserhalmi, Ádám Csincsi, József Lázár, and László Takács

9:35 AM

12

Mechanism of action of complement factor H as a therapeutic in AMD

Robyn Biggs, Adam Tellier, Scott Lauder, and Suresh Katti

9:50 AM

13

ARGX-117, an inhibitory C2 antibody with sweeping properties leading to sustained in vivo activity

Inge Van de Walle, Kevin Budding, Karen Silence, Liesbeth Van de Ven, Kim Dijkxhoorn, Elisabeth de Zeeuw, cafer Yildiz, Sofie Gabriels, Jean-Michael Percier, Johanna Wildemann, Jan Meeldijk, Peter Simons, Louis Boon, Linda Cox, Rolf Urbanus, Henny Otten, Jeanette Leusen, Christophe Blanchetot, Hans de Haard, Erik Hack, and Peter Boross

10:05 AM

14

Clearance of amyloid-beta with bispecific antibody constructs bound to erythrocytes

Ronald Taylor, Margaret Lindorfer, and John Atkinson

10:25 AM

15

Overcoming incomplete blockage at the level of C3 and C5 by developing a triple fusion protein that reliably inhibits all complement pathways

Marco Mannes, Markus Huber-Lang, and Christoph Schmidt

10:40 AM

Coffee Break and Poster Viewing

SESSION IV

Structure and mechanisms of activation, regulation and crosstalk

Chairs: Ilse Jongerius and Piet Gros

11:40 AM

16

Insights into complement activation by cryo-EM

Piet Gros

12:00 AM

17

The contribution of the alternative pathway to complement activation depends on the strength of classical pathway initiation

Esther de Boer, Astrid Thielen, Jeroen Langereis, Angela Kamp, Mieke Brouwer, Nienke Oskam, Theo Rispens, Diana Wouters, and Ilse Jongerius

12:15 PM

18

Both extracellular and intracellular complement participate in inflammasome activation induced by cholesterol crystals

Nathalie Niyonzima, Siril Bakke, Bente Halvorsen, Claudia Kemper, Tom Mollnes, and Terje Espevik

12:35 PM

19

Factor H related protein 1 (FHR1) : a marker of inflammation?

Christine Skerka

12:55 PM

20

Air bubbles activate complement and trigger C3-dependent coagulation and cytokine release in vitro in human whole blood

Benjamin Storm, Dorte Christiansen, Hilde Fure, Judith Ludviksen, Corinna Lau, John Lambris, Trent Woodruff, Tonje Braaten, Erik Nielsen, and Tom Mollnes

13:15 PM

Lunch and Informal Discussions

7:30 PM

Dinner and Informal Discussions

September 11

SESSION V

Complement targets and biomarkers in immune and inflammatory diseases

Chairs: Markus Hoffmann and Markus Huber-Lang

9:00 AM

21

Targeting the complosome for preventing flares in inflammatory diseases

Markus Hoffmann

9:20 AM

22

Biomarker studies of pulmonary mucosa in asymptomatic preclinical rheumatoid arthritis subjects and RNA profiling in the early rheumatoid arthritis synovium suggest multiple independent pathogenic roles for complement activation

Nirmal Banda, Myles Lewis, Kevin Deane, Yuko Okamoto, Jennifer Seifert, Costantino Pitzalis, Kristen Demoruelle, and Michael Holers

9:40 AM

23

Complement implication in acute kidney injury associated with rhabdomyolysis

Anne Grunenwald, Victoria Poillerat, Idris Boudhabhay, Steven Sacks, Laurent Gilardin, and Lubka Roumenina

9:55 AM

24

CFI rare variants associated with macular thinning and age-related macular degeneration in the UK Biobank

Nikolaos Tzoumas, David Kavanagh, Andrew Lotery, and David Steel

10:10 AM

25

Differential therapy of anaphylatoxin modulation after polytrauma, sepsis and multiple organ failure

Markus Huber-Lang, Marco Mannes, John Lambris, Rebecca Halbgebauer

10:30 AM

Coffee Break and Poster Viewing

SESSION VI

Complement targets and biomarkers in immune and inflammatory diseases

Chairs: George Hajishengallis and Christine Gaboriaud

11:40 AM

26

C3 Glomerulopathy: Factor H-related gene and protein alterations and improving complement diagnoses in human kidneys

Peter Zipfel

12:00 PM

27

C1s and C1r complement proteins abnormality in periodontal Ehlers-Danlos syndrome

Veronique Rossi, Isabelle Bally, Fabien Dalonneau, Nicole Thielens, and Christine Gaboriaud

12:15 PM

28

Monitoring urine sC5b-9 with high sensitivity method reveals multiple distinct lupus nephritis subgroups: Potential implications for complement-targeted drug development

Michelle Elvington, Alfred Kim, Deepali Sen, Nancy Mathis, Rebecca Schriefer, Robin Bruchas, John Atkinson, Ronan O'Shaunessy, Niamh O'Luanaigh, and Martin Schmidt

12:30 PM

29

A novel method to store complement C3 with superior ability to maintain the native structure and function of the protein

Anna Adler, Vivek Anand Manivel, Karin Fromell, Kristina Nilsson Ekdahl, Yuji Teramura, and Bo Nilsson

12:45 PM

Lunch and Informal Discussions

15:00 PM

(CITY TOUR)

7:30 PM

Dinner and Informal Discussions

September 12

SESSION VII

Therapeutic modulation of complement in COVID-19

Chairs: Christine Skerka and Bo Nilsson

9:00 AM

30

Thromboinflammation in COVID-19

Bo Nilsson, Oskar Eriksson, Barbro Persson, Karin Fromell, and Kristina Ekdahl

9:20 AM

31

The pervasive role of complement dysregulation in severe COVID-19: An update on an evolving clinical landscape with multiple therapeutic opportunities

Dimitrios Mastellos, Panagiotis Skendros, Markus Huber-Lang, Rodrigo Calado, Antonio Risitano, Konstantinos Ritis, Despina Yancopoulou, and John Lambris

9:40 AM

32

Complement activation and thrombogenic NETs in COVID-19 immunothrombosis

Akrivi Chrysanthopoulou, Panagiotis Skendros, Alexandros Mitsios, Dimitrios  Mastellos, Maria  Ntinopoulou, Petros  Rafailidis, Simeon  Metallidis, Eleni  Sertaridou, Victoria  Tsironidou, Christina  Tsigalou, Maria  Tektonidou, Theocharis  Konstantinidis, Charalampos  Papagoras, Ioannis  Mitroulis, Georgios  Germanidis, John  Lambris, and Konstantinos  Ritis

9:55 AM

33

Targeting complement C3 with AMY-101 in COVID-19-associated ARDS: interim results from the ITHACA phase 2 randomized, placebo-controlled trial

Panagiotis Skendros, Georgios Germanidis, Dimitrios Mastellos, Christina Antoniadou, Efstratios Gavriilidis, Georgios Kalopitas, Anna  Samakidou, Angelos  Liontos, Akrivi Chrysanthopoulou, Maria Ntinopoulou, Dionysios Kogias, Ioanna karanika, Andreas Smyrlis, Dainora Cepaityte, Iliana Fotiadou, Nikoleta  Zioga, Ioannis Mitroulis, Nikolaos Gatselis, Charalampos Papagoras, Simeon  Metallidis, Haralampos Milionis, George Dalekos, Markus Huber-Lang, Antonio Risitano, Simona Iacobelli, Loek Willems, Barbro Persson, Vivek Anand Manivel, Bo Nilsson, E. Sander Connolly, Despina Yancopoulou, Konstantinos Ritis, and John Lambris

10:15 AM

34

Human Coronavirus infected lung cells recruit complement inhibitors vitronectin and clusterin and delay complement-mediated lysis

Candace Fox and Griffith Parks

Special Session

Tribute to Jules Bordet

Chairs: John Lambris and Ronald Taylor.

10:30 AM

35

Keynote Lecture

Jules Bordet, a visionary polymath

Jean-Marc Cavaillon

11:00 AM

Coffee Break and Poster Viewing

SESSION VIII

Therapeutic modulation of complement in COVID-19

Chairs: Cecilia Garlanda and Panagiotis Skendros

11:45 AM

36

Complement activation in the disease course of coronavirus disease 2019 and its effects on clinical outcomes

Aline de Nooijer, Inge Grondman, Nico Janssen, Mihai Netea, Loek Willems, Frank van de Veerdonk, Evangelos Giamarellos-Bourboulis, Erik Toonen, and Leo Joosten

12:00 AM

37

Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules

Matteo Stravalaci, Isabel Pagani, Elvezia Paraboschi, Mattia Pedotti, Andrea Doni, Francesco Scavello, Sarah Mapelli, Marina Sironi, Luca Varani, Milos Matkovic, Andrea Cavalli, Daniela Cesana, Pierangela Gallina, Nicoletta Pedemonte, Valeria Capurro, Nicola Clementi, Nicasio Mancini, Pietro Invernizzi, Rino Rappuoli, Stefano Duga, Barbara Bottazzi, Mariagrazia Uguccioni, Rosanna Asselta, Elisa Vicenzi, Alberto Mantovani, and Cecilia Garlanda

12:15 PM

38

John P Ioannidis

12:55 PM

Closing remarks

13:15 PM

Lunch and Informal Discussions

8:00 PM

Farewell dinner